Notably, our studies have highlighted a role of IL-33 in systemic manifestations of malignant diseases, such as inflammation-related anaemia and thrombocytosis in advanced stages of colorectal cancer, suggesting that IL-33 may modulate not only local immune responses but also systemic alterations associated with disease progression [76,77]. Here, IL33 is linked to thrombocytosis disease.